Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Electronic Theses and Dissertations bannerUC San Diego

The role of methylation in t(8;21) acute myeloid leukemia : potential therapeutic targets of leukemic pathogenesis

Abstract

The fusion protein, AML1-ETO (AE) is generated from the translocation 8;21 (q22;q22) [(t8;21)] translocation and is identified in 12-15% of de novo cases of human acute myeloid leukemia (AML). However, AML1-ETO alone is not capable of inducing leukemia in a murine transduction model, while an alternatively spliced isoform, AML1-ETO9a (AE9a), is. The resulting leukemia is a product of the effect of the AE9a transcription factor on gene expression, including that of AML1 target genes. It has been postulated that one of the mechanisms through which AE/ AE9a alter gene expression is via the recruitment of DNA methyltransferases, which it uses to methylate genes and subsequently downregulate their expression. To investigate the role of DNA methylation in gene downregulation in t(8;21) AML, I treated t(8;21) and non-t(8;21) expressing human and murine AML cells with the DNA hypomethylating drug 5-aza-2'-deoxycytidine (decitabine) to discern its effects on t(8;21) downregulated genes via RT-qPCR. From the genes that were upregulated following treatment with decitabine, I identified which are methylated based on published genome wide DNA methylation profiling study in human AML cases, and selected 4 genes of interest for study: Cuedc1, Jdp2, Fam134b, and Rgs18. To further investigate the importance of downregulation of my genes of interest, I used a retroviral vector to re-express them in a murine AML1-ETO leukemia derived cell line and observed the changes in morphology and cell survival. Finally, I attempt to confirm the methylation status of the genes of interest with bisulfite treatment